Challenging the Notion that "Cancer is Universally Incurable": An Evidence-Based Investigation by a Citizen Scientist

Marie Seshat Landry, AI Assistance Acknowledgement: This document was significantly enhanced, structured, and expanded with the assistance of OpenAI's ChatGPT and Google's Gemini models.[1]

[1]Marie Landry's Spy Shop (OSINT Division)
[2]Global Organic Solutions (Scientific Inquiry Unit)

April 2, 2025

Abstract

Abstract: The pervasive belief that cancer is universally incurable casts a long shadow, influencing public perception, patient morale, and even healthcare decisions. This notion frequently clashes with the reality presented by decades of scientific advancement. As an independent citizen scientist, my investigation aimed to evaluate this claim of universal incurability using the scientific method. The central hypothesis is that this claim is factually incorrect. Evidence was gathered from peer-reviewed journals, clinical trial databases, and reputable health organizations. This analysis demonstrates that numerous cancer types, especially when detected early, are curable through conventional therapies. Furthermore, many other cancers can be managed effectively, leading to long-term remission. This review also evaluates the landscape of complementary and alternative medicine (CAM), emphasizing the critical distinction between scientifically validated adjunctive therapies and unproven claims of cures. While acknowledging the challenges posed by advanced cancers, the synthesis of publicly available evidence powerfully refutes the myth of universal incurability. This document argues for the importance of disseminating accurate, evidence-based information to foster realistic hope.

1 Introduction: An Independent Inquiry into a Persistent Belief

The notion that "cancer is incurable" often feels like an immutable truth. For generations, a cancer diagnosis was perceived as a death sentence. Early medical understanding was limited, and treatments were rudimentary. This history has cast a long shadow, contributing to a public perception that, despite breakthroughs, cancer remains fundamentally unconquerable.

From my perspective as a citizen scientist and OSINT practitioner, this belief seemed discordant with the sheer volume of scientific progress documented in publicly accessible databases. If people widely believe cancer is incurable, it can lead to despair, potentially delaying diagnosis and influencing patients to abandon evidence-based treatments for unproven alternatives based on false hope.

The reality, as revealed by decades of research, is that the landscape of cancer science and treatment has undergone a transformation. Fields like molecular biology, genomics, immunology,

and pharmacology have converged, yielding therapies of remarkable sophistication and efficacy. These represent paradigm shifts, moving from relatively blunt instruments to highly targeted drugs and immunotherapies. The results are tangible: improved survival rates and outright cures for many cancers.

Simultaneously, there's a burgeoning interest in complementary and alternative medicine (CAM). While some approaches offer support for well-being or symptom management, others make claims of cures that lack rigorous scientific backing. Investigating these claims with scientific rigor is essential.

This document represents my effort to apply the scientific method to challenge the statement "cancer is incurable." The goal is to rigorously examine the evidence available to any diligent researcher. By systematically analyzing data from clinical trials, systematic reviews, and large oncological databases, this investigation seeks to replace myth with evidence, fostering a perspective grounded in realistic hope.

2 Research Question: Scrutinizing the "Incurable" Claim with Data

The central question guiding this investigation became: *Based on a critical review of publicly available scientific and clinical data, is the generalized statement "cancer is universally incurable" factually supported?*

3 Hypothesis: The "Incurable" Generalization is Falsifiable by Evidence

My working hypothesis was formulated: *The statement "cancer is incurable" is a factually incorrect generalization that can be falsified by examining robust, publicly accessible evidence.* This hypothesis rests on several pillars:

- **Documented Cures via Standard Oncology:** Substantial evidence demonstrates that numerous specific cancer types and stages have high cure rates when treated with standard medical protocols.
- **Achieving Durable Long-Term Remission:** Conventional treatments often lead to durable, long-term remission for many cancers, allowing individuals to live full lives.
- **Investigated Potential of Other Modalities:** Rigorous scientific investigation into certain CAM approaches reveals biological activity, adding complexity that challenges absolute therapeutic nihilism.
- **The Biological Outlier: Spontaneous Remission:** The documented phenomenon of spontaneous cancer remission highlights the complex interplay between tumor and host.

The objective of this investigation is to systematically gather and evaluate the evidence pertaining to these points.

4 Methodology: An AI-Assisted Approach to Information Synthesis

This investigation leverages advanced AI tools to gather, synthesize, and evaluate publicly available information pertinent to the curability of cancer.

4.1 Process Outline

The creation of this document followed these primary steps:

1. **Initial Structuring:** An outline was generated using OpenAI's ChatGPT. 2. **Content Generation and Expansion:** Google's Gemini/AI Studio models were utilized extensively to generate detailed content. 3. **Iterative Refinement:** The author engaged in an iterative process with the AI tools for enhancements and clarifications. 4. **AI-Assisted Critique and Citation:** The AI tools were prompted to critique the text and identify relevant citations from the scientific literature. 5. **Finalization and Formatting:** AI assistance was used for final proofreading and ensuring consistent formatting.

4.2 Author's Role and Evaluation Criteria

The author's role was crucial in:

- Defining the research question and hypothesis.
- Providing foundational prompts.
- Critically evaluating the AI-generated output for accuracy and relevance.
- Ensuring the final narrative reflected the synthesized information and the author's judgment.

This methodology allows an independent researcher to rapidly access and synthesize vast amounts of information.

5 Results: Unpacking the Evidence Against Universal Incurability

My investigation revealed compelling evidence contradicting the notion that cancer is universally incurable. The findings fall into several key categories:

5.1 Category 1: Demonstrable Cures Through Conventional Oncology

For numerous cancers, particularly when caught early, established medical treatments offer a high probability of cure.

- **Testicular Cancer:** Combination chemotherapy regimens achieve cure rates over 95% for early-stage disease.
- **Hodgkin's Lymphoma:** Cure rates today often exceed 80-90%.
- **Childhood Acute Lymphoblastic Leukemia:** Cure rates approaching or exceeding 90% in major pediatric oncology centers.

- **Gestational Trophoblastic Disease:** High cure rates with appropriate treatment.
- **Early-Stage Solid Tumors:** Localized treatments lead to very high cure rates for many common cancers.

The volume and consistency of data across reputable sources provide evidence against the generalization that "cancer is incurable."

5.2 Category 2: Durable Long-Term Remission

Modern treatments can induce durable, long-term remission for many cancers, allowing patients to live fulfilling lives.

- **Chronic Myeloid Leukemia:** Transformed into a manageable chronic condition with near-normal life expectancy.
- **Indolent Lymphomas:** Long periods of remission spanning decades.
- **Metastatic Cancers with New Therapies:** Immunotherapy has produced durable, long-term responses in some patients.

5.3 Category 3: Evaluating CAM and Phytochemicals

The world of CAM requires careful navigation, applying the same critical lens used for conventional medicine.

- **Preclinical Promise vs. Clinical Reality:** Many phytochemicals show intriguing anti-cancer activity in lab studies, but translating this to human efficacy is a major hurdle.
- **Understanding Clinical Trial Phases:** Many CAM interventions haven't progressed through rigorous testing for cancer treatment indications.
- **Integrative Oncology vs. Alternative "Cures":** Evidence-based complementary therapies support patient well-being when used alongside conventional treatment.
- **The Dangers of Substitution:** Studies show worse survival outcomes for patients who abandon standard medical care for unproven alternatives.

5.4 Category 4: The Enigma of Spontaneous Remission

While rare, spontaneous remission of confirmed cancer cannot be ignored. Documented cases exist and serve as a testament that cancer is not inevitably progressive.

6 Conclusion: Replacing Myth with Evidence-Based Hope

The generalized statement “cancer is incurable” is a demonstrably false and outdated myth. This assertion is not supported by the vast body of publicly accessible scientific literature.

The primary pillars supporting this conclusion are:

1. Proven, high cure rates for numerous cancer types achieved through decades of progress in conventional oncology.
2. Durable, long-term remission for many cancers, transforming them into manageable chronic conditions.
3. Clear distinction between evidence-based integrative approaches and unproven alternative therapies.
4. The rare phenomenon of spontaneous remission serves as a counterexample to absolute incurability.

While the fight against cancer remains challenging, the narrative must shift from one of universal incurability to one of complexity, ongoing progress, and evidence-based hope. For many, cancer is survivable, manageable, and indeed, curable.

7 Implications for Public Understanding and Communication: Empowering Citizens

The findings of this investigation carry significant implications for how we talk about and understand cancer. Perpetuating the myth of universal incurability is actively harmful.

Empowering citizens requires a shift towards communication that is:

- **Accurate and Nuanced:** Clearly stating that many cancers *are* curable with standard treatments, while acknowledging the challenges of others.
- **Evidence-Based:** Grounding hope in demonstrable scientific progress and verifiable data.
- **Distinguishing Outcomes:** Differentiating between cure, long-term remission/control, and palliative care.
- **Highlighting Progress:** Communicating the dynamic nature of cancer research and the continuous development of better therapies.
- **Critical about CAM:** Promoting scientific literacy to evaluate claims about CAM, distinguishing supportive integrative care from potentially harmful alternative "cures."
- **Encouraging Dialogue:** Fostering open conversations about realistic prognoses and evidence-based options.

Organizations like the NCI, WHO, and major cancer charities play a vital role. By grounding our understanding in evidence, we can challenge the myth and foster a climate of informed, realistic hope.

8 Key Resource Databases and Organizations

Note: The following are valuable starting points for independent research.

- PubMed / PubMed Central (PMC)
- ClinicalTrials.gov
- NCI SEER Database
- National Cancer Institute (NCI)
- World Health Organization (WHO) - Cancer
- American Society of Clinical Oncology (ASCO)
- National Comprehensive Cancer Network (NCCN)
- Cochrane Library
- Google Scholar

References

[1] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74.

[2] Mukherjee S. The Emperor of All Maladies: A Biography of Cancer. New York: Scribner; 2010.

[3] DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019.

[4] Spiegel D. Psychosocial aspects of breast cancer treatment. Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-36-S1-47.

[5] Johnson SB, Park HS, Gross CP, Yu JB. Use of alternative medicine for cancer and its impact on survival. J Natl Cancer Inst. 2018 Aug 1;110(1):121-124.

[6] Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004 Jul;10(7):789-99.

[7] Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016 May 18;14:73.

[8] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018 Mar 23;359(6382):1350-1355.

[9] Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019 Jul;69(5):363-385.

[10] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30.

[11] National Center for Complementary and Integrative Health (NCCIH). Cancer. [Accessed specific date]. Available from: https://www.nccih.nih.gov/health/cancer

[12] Vickers AJ, Kuo J, Cassileth BR. Unconventional therapies for cancer and cancer-related symptoms. Lancet Oncol. 2006 Aug;7(8):677-84.

[13] Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009 Apr 9;458(7239):719-24.

[14] National Cancer Institute (NCI). Cancer Stat Facts Sheets. [Accessed specific date]. Available from: https://seer.cancer.gov/statfacts/

[15] Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5;344(14):1031-7.

[16] Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007 Nov-Dec;4(6):807-18.

[17] Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila). 2009 Apr;2(4):409-18.

[18] Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 1990;29(5):545-50.

[19] Cole WH, Everson TC. Spontaneous regression of cancer: preliminary report. Ann Surg. 1956 Jun;144(3):366-83.

[20] Einhorn LH, Williams SD. Chemotherapy of disseminated testicular cancer. Cancer. 1980 Oct 1;46(7):1339-44.

[21] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version [e.g., 1.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

Sure! Here's the continuation from the Feldman reference:

"'latex

[22] Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008 Feb 13;299(6):672-84.

[23] Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84.

[24] DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970 Jun;73(6):881-95.

[25] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. Version [e.g., 2.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

[26] Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006 Jan 12;354(2):166-78.

[27] Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015 Oct 15;373(16):1541-52.

[28] Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2012 Feb;26(1):111-31.

[29] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gestational Trophoblastic Neoplasia. Version [e.g., 1.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

[30] National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer. [Accessed specific date]. Available from: https://seer.cancer.gov/statfacts/html/breast.html.

[31] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011 Aug 27;378(9793):771-84.

[32] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version [e.g., 4.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

[33] Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE; SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011 May 5;364(18):1708-17.

[34] National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. [Accessed specific date]. Available from: https://seer.cancer.gov/statfacts/html/prost.html.

[35] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version [e.g., 2.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

[36] Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20;27(36):6199-206.

[37] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version [e.g., 2.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

[38] Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133.

[39] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version [e.g., 1.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

[40] André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; MOSAIC Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3;350(23):2343-51.

[41] National Cancer Institute. SEER Cancer Stat Facts: Colon and Rectum Cancer. [Accessed specific date]. Available from: https://seer.cancer.gov/statfacts/html/colorect.html.

[42] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version [e.g., 2.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

[43] World Health Organization (WHO). Cervical cancer. [Accessed specific date]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.

[44] National Cancer Institute. SEER Cancer Stat Facts: Cervical Cancer. [Accessed specific date]. Available from: https://seer.cancer.gov/statfacts/html/cervix.html.

[45] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version [e.g., 1.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

[46] Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 Aug;30(8):1044-54.

[47] Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016 Aug 20;34(24):2851-7.

[48] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas (includes Follicular). Version [e.g., 5.2023]. [Accessed specific date]. Available from: https://www.nccn.org.

[49] Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23.

[50] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Tykodi FJ, Garon EB, Hurwitz HI, Goldberg MV, Albertini MR, Gordon MS, Loo K, Galea E, Li X, Horak CE, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54.

[51] Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and normal tissues. Nutr Cancer. 2010;62(7):919-30.

[52] Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev. 2014 Jan;66(1):222-307.

[53] Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Jan;15(1):195-218.

[54] Walle T, Humpeler S, Walle UK. Resveratrol glucuronidation and sulphation in the human liver. Xenobiotica. 2001 Nov;31(11):789-97.

[55] Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, Brown K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010 Oct 1;70(19):7392-9.

[56] Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012 Jun;12(6):436-44.

[57] Dariš B, Tancer Verboten M, Knez Ž, Ferk P. Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosn J Basic Med Sci. 2019 Feb 20;19(1):14-23.

[58] Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015 Jun 23-30;313(24):2456-73.

[59] Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther. 2015 Aug;97(6):575-86.

[60] Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst. 1993 Nov 3;85(13):1038-49.

[61] Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr. 2000 Jun;71(6 Suppl):1698S-702S.

[62] Yuan JM. Cancer prevention by green tea: evidence from epidemiologic studies. Am J Clin Nutr. 2013 Dec;98(6 Suppl):1676S-81S.

[63] Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006 Jan 15;66(2):1234-40.

[64] Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kenderian SS, Davis ME, Kay NE. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2013 Feb 1;119(2):363-70.

[65] National Center for Complementary and Integrative Health (NCCIH). Clinical Trials. [Accessed specific date]. Available from: https://www.nccih.nih.gov/research/clinical-trials.

[66] Deng GE, Cassileth BR, Yeung KS. Complementary therapies in cancer care. Oncology (Williston Park). 2005 Sep;19(10):1333-8; discussion 1338, 1343-4, 1347.

[67] Johnson SB, Park HS, Gross CP, Yu JB. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncol. 2017 Oct 1;4(10):1375-1381.

[68] Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther. 2010 Jun;9(2):142-57.

[69] Ostermann T, Blaser G, Bertram M, Schad F, Matthes H, Hübner J. Systematic Review and Meta-Analysis on the Survival of Cancer Patients Treated with a Mistletoe Extract (Iscador): An Update of Findings. Complement Med Res. 2020;27(4):260-271.

[70] Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res. 2009 Jul;29(7):2739-45.

[71] Papac RJ. Spontaneous regression of cancer: possible mechanisms. In Vivo. 1998 Nov-Dec;12(6):571-8.

[72] Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010 Apr-May;1805(1):105-17.

[73] Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to targeted therapies. Nat Rev Clin Oncol. 2018 Feb;15(2):81-94.

[74] American Cancer Society. Cancer Facts & Figures 2020. Special Section: Cancer Disparities. Atlanta: American Cancer Society; 2020. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html